Nicholas Grund
2017
In 2017, Nicholas Grund earned a total compensation of $1.5M as Chief Commercial Officer at AMAG Pharmaceuticals, a 34% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $203,940 |
|---|---|
| Option Awards | $280,490 |
| Salary | $470,078 |
| Stock Awards | $536,200 |
| Other | $8,100 |
| Total | $1,498,808 |
Grund received $536.2K in stock awards, accounting for 36% of the total pay in 2017.
Grund also received $203.9K in non-equity incentive plan, $280.5K in option awards, $470.1K in salary and $8.1K in other compensation.
Rankings
In 2017, Nicholas Grund's compensation ranked 6,990th out of 14,666 executives tracked by ExecPay. In other words, Grund earned more than 52.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,990 out of 14,666 | 52nd |
Division Manufacturing | 2,592 out of 5,768 | 55th |
Major group Chemicals And Allied Products | 841 out of 2,074 | 60th |
Industry group Drugs | 654 out of 1,730 | 62nd |
Industry Pharmaceutical Preparations | 513 out of 1,329 | 61st |
Source: SEC filing on April 25, 2018.
Grund's colleagues
We found four more compensation records of executives who worked with Nicholas Grund at AMAG Pharmaceuticals in 2017.